

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxx

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.			

Updated Search

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 20:02:56 ON 06 NOV 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'REGISTRY' ENTERED AT 20:05:19 ON 06 NOV 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 NOV 2008 HIGHEST RN 1070955-84-8
 DICTIONARY FILE UPDATES: 5 NOV 2008 HIGHEST RN 1070955-84-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
 Uploading C:\Documents and Settings\brobinson1\My Documents\dafsatt.str

L1 STRUCTURE UPLOADED

=> s l1
 SAMPLE SEARCH INITIATED 20:17:02 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE

Updated Search



=> s l4 and bailey, m?/au
 1263 BAILEY, M?/AU
 L5 3 L4 AND BAILEY, M?/AU

=> d l5, ibib abs hitstr, 1-3

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:1009763 HCAPLUS
 DOCUMENT NUMBER: 149:268327
 TITLE: Preparation of peptides as inhibitors of hepatitis C
 virus NS3 protease
 INVENTOR(S): Bailey, Murray D.; Bilodeau, Francois;
 Forgione, Pasquale; Gorys, Vida; Llinas-Brunet,
 Montse; Naud, Julie; O'Meara, Jeffrey; Poupart,
 Marc-Andre
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;
 Boehringer Ingelheim Pharma G.m.b.H. & Co K.-G.
 SOURCE: PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008098368	A1	20080821	WO 2008-CA293	20080215
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-890304P P 20070216
 OTHER SOURCE(S): MARPAT 149:268327
 GI



AB The invention relates to tripeptides I [R1 is (halo)alk(en)yl; R2 is alkoxy; R2a is substituted Ph or biphenyl; R3 is (un)substituted alkyl, cycloalkyl, or cycloalkylalkyl; R4 is cycloalkyl, alkylcycloalkyl, or (alkyl)amino; R5 is (un)substituted alkyl or cycloalk(en)yl], including diastereoisomers, tautomers, or salts, which are useful as inhibitors of the HCV NS3 protease. Thus, tripeptide II was prepared via coupling of prolyl dipeptide and aminocyclopropanecarboxamide intermediates in the presence of HATU and diisopropylamine. Compds. of the invention show unexpectedly good activity or activity below 50 nM when tested in the NS3-NS4A protease and the cell-based luciferase reporter HCV RNA replication assays.

IT 1047995-54-9P 1047995-61-8P 1047995-66-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides as inhibitors of hepatitis C virus NS3 protease)

RN 1047995-54-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-methoxy-4-[4-(3-methyl-2-furanyl)phenyl]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1047995-61-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-methoxy-4-[4-(1-methyl-1H-indol-5-yl)phenyl]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1047995-66-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-methoxy-4-[4-(3-methyl-2-thienyl)phenyl]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:15038 HCAPLUS

DOCUMENT NUMBER: 144:108608

TITLE: Preparation of peptide analogs as hepatitis C inhibitors

INVENTOR(S): Bailey, Murray D.; Bhardwaj, Punit; Forgione, Pasquale; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-Brunet, Montse; Poupart, Marc-Andre; Rancourt, Jean

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co KG; Bailey, Murray D.; Bhardwaj, Punit; Forgione, Pasquale; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-Brunet, Montse; et al.

SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006000085	A1	20060105	WO 2005-CA967	20050622
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,			

KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 CA 2556669 A1 20060105 CA 2005-2556669 20050622
 EP 1763531 A1 20070321 EP 2005-759498 20050622
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2008504240 T 20080214 JP 2007-516924 20050622
 US 20060258868 A1 20061116 US 2006-595108 20060217
 PRIORITY APPLN. INFO.: US 2004-583543P P 20040628
 WO 2005-CA967 W 20050622
 OTHER SOURCE(S): CASREACT 144:108608; MARPAT 144:108608
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to peptides I [n, m are 1 or 2; R1 is H, (halo)alkyl, (halo)alkenyl or (halo)alkynyl; R2 is CH2-R7, NH-R7, O-R7, S-R7, SO-R7, SO2-R7, CH2O-R7 or O-X-R7, where X is alkylene, alkenylene or alkynylene and R7 is (un)substituted aryl or heterocyclyl; R3 is (un)substituted alkyl or cycloalkyl; R5 is B, B-CO, B-O2C, B-NR8CO, B-NR8CS, B-SO2 or B-NR8SO2, where B is (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl and R8 is H or alkyl; R4, R6 are independently H, (un)substituted alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl; or NR4R6 may form a ring; Y is H or alkyl (with provisos)] or diastereomers or salts for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compds. II which can be reacted with an amide anion to produce compds. I. Thus, peptide III was prepared via peptide coupling in solution with cleavage of the azalactone intermediate by sulfamoylpyrroline in the last step.

IT 1043019-37-9 1043019-38-0 1043019-39-1
 1043019-40-4 1043019-41-5 1043019-42-6
 1043019-43-7 1043019-44-8 1043019-45-9
 1043019-46-0 1043019-47-1 1043019-48-2
 1043019-49-3 1043019-50-6 1043019-51-7
 1043019-52-8 1043019-53-9 1043019-54-0
 1043019-55-1 1043019-56-2 1043019-57-3
 1043019-58-4 1043019-59-5 1043019-60-8
 1043019-61-9 1043019-62-0 1043019-63-1
 1043019-65-3 1043019-66-4 1043019-67-5
 1043019-68-6 1043019-69-7 1043019-70-0
 1043019-71-1 1043019-72-2 1043019-73-3
 1043019-74-4 1043019-75-5 1043019-76-6
 1043019-77-7 1043019-78-8 1043019-79-9
 1043019-80-2 1043019-81-3 1043019-82-4
 1043019-84-6 1043019-85-7 1043019-86-8
 1043019-87-9 1043019-88-0 1043019-89-1
 1043019-90-4 1043019-91-5 1043019-92-6
 1043019-93-7 1043019-94-8 1043019-95-9
 1043019-96-0 1043019-97-1 1043019-98-2
 1043019-99-3 1043020-00-3 1043020-01-4
 1043020-02-5 1043020-03-6 1043020-04-7
 1043020-05-8 1043020-06-9 1043020-07-0

1043020-11-6	1043020-15-0	1043020-18-3
1043020-21-8	1043020-23-0	1043020-27-4
1043020-28-5	1043020-31-0	1043020-33-2
1043020-35-4	1043020-36-5	1043020-37-6
1043020-38-7	1043020-39-8	1043020-40-1
1043020-41-2	1043020-42-3	1043020-43-4
1043020-44-5	1043020-45-6	1043020-46-7
1043020-47-8	1043020-48-9	1043020-49-0
1043020-50-3	1043020-52-5	1043020-53-6
1043020-54-7	1043020-55-8	1043020-56-9
1043020-57-0	1043020-58-1	1043020-59-2
1043020-60-5	1043020-61-6	1043020-62-7
1043020-63-8	1043020-64-9	1043020-65-0
1043020-66-1	1043020-67-2	1043020-68-3
1043020-69-4	1043020-70-7	1043020-71-8
1043020-72-9	1043020-73-0	1043020-74-1
1043020-75-2	1043020-76-3	1043020-77-4
1043020-78-5	1043020-80-9	1043020-81-0
1043020-84-3	1043020-87-6	1043020-89-8
1043020-90-1	1043020-91-2	1043020-92-3
1043020-93-4	1043020-94-5	1043020-95-6
1043020-96-7	1043020-97-8	


RL: PRPH (Prophetic)

(Preparation of peptide analogs as hepatitis C inhibitors)

RN 1043019-37-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-38-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

Updated Search




RN 1043019-39-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-40-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-41-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-42-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-43-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-44-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-45-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-46-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-47-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043019-48-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 1043019-49-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-50-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-51-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-52-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-53-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-54-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-55-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-56-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-57-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-58-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-59-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-60-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-61-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-62-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043019-63-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Absolute stereochemistry.




Absolute stereochemistry.




RN 1043019-67-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-68-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-69-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-70-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-71-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043019-72-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Absolute stereochemistry.




Absolute stereochemistry.




RN 1043019-75-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A






RN 1043019-76-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-77-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-78-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-79-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-80-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-81-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-82-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-84-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




```

RN      1043019-85-7   HCAPLUS
CN      INDEX NAME NOT YET ASSIGNED

```

Absolute stereochemistry.




```

RN      1043019-86-8   HCAPLUS
CN      INDEX NAME NOT YET ASSIGNED


```

Absolute stereochemistry.



RN 1043019-87-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043019-88-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Absolute stereochemistry.




Absolute stereochemistry.




RN 1043019-91-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-92-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-93-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-94-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043019-95-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A






RN 1043019-96-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-97-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-98-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-99-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-00-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-01-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-02-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-03-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-04-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-05-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-06-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-07-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-11-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-15-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-18-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-21-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-23-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-27-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-28-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A






RN 1043020-31-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-33-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-35-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 1043020-36-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 1043020-37-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Updated Search

Absolute stereochemistry.




RN 1043020-38-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-39-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-40-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-41-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-42-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-43-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-44-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-45-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-46-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-47-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-48-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-49-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-50-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-52-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-53-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-54-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


Absolute stereochemistry.






RN 1043020-57-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-58-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-59-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-60-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-61-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A






RN 1043020-62-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-63-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-64-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-65-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-66-1 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1043020-67-2 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

Absolute stereochemistry.




RN 1043020-70-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-71-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-72-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-73-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-74-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-75-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-76-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-77-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-78-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A





RN 1043020-80-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-81-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 1043020-84-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-87-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-89-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Absolute stereochemistry.




Absolute stereochemistry.




RN 1043020-92-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-93-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-94-5 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-95-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-96-7 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-97-8 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 872497-04-6P 872497-05-7P 872497-09-1P
 872497-10-4P 872497-12-6P 872497-13-7P
 872497-16-0P 872497-17-1P 872497-18-2P
 872497-19-3P 872497-21-7P 872497-22-8P
 872497-33-1P 872497-34-2P 872497-35-3P
 872497-36-4P 872497-37-5P 872497-38-6P
 872497-39-7P 872497-40-0P 872497-41-1P
 872497-42-2P 872497-43-3P 872497-44-4P
 872497-45-5P 872497-46-6P 872497-47-7P
 872497-48-8P 872497-49-9P 872497-50-2P
 872497-51-3P 872497-52-4P 872497-53-5P
 872497-54-6P 872497-55-7P 872497-56-8P
 872497-57-9P 872497-58-0P 872497-59-1P
 872497-60-4P 872497-61-5P 872497-62-6P
 872497-63-7P 872497-64-8P 872497-65-9P
 872497-66-0P 872497-67-1P 872497-68-2P
 872497-69-3P 872497-70-6P 872497-71-7P
 872497-72-8P 872497-73-9P 872497-74-0P
 872497-75-1P 872497-76-2P 872497-77-3P
 872497-78-4P 872497-79-5P 872497-80-8P
 872497-81-9P 872497-82-0P 872497-83-1P
 872497-84-2P 872497-85-3P 872497-86-4P
 872497-87-5P 872497-88-6P 872497-89-7P
 872497-90-0P 872497-91-1P 872497-92-2P
 872497-93-3P 872497-94-4P 872497-95-5P
 872497-96-6P 872497-97-7P 872497-98-8P
 872497-99-9P 872498-00-5P 872498-01-6P
 872498-02-7P 872498-03-8P 872498-04-9P
 872498-05-0P 872498-06-1P 872498-07-2P
 872498-08-3P 872498-09-4P 872498-10-7P
 872498-11-8P 872498-12-9P 872498-13-0P
 872498-14-1P 872498-15-2P 872498-16-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide analogs as hepatitis C inhibitors)

RN 872497-04-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-05-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-04-6

CMF C36 H49 Cl N6 O9 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872497-09-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-10-4 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-09-1

CMF C40 H54 N6 O10 S


Absolute stereochemistry.



Updated Search

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 872497-12-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-13-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-12-6
 CMF C37 H51 Br N6 O10 S

Absolute stereochemistry.


Updated Search



CM 2

CRN 76-05-1



CMF C2 H F3 O2



RN 872497-16-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 872497-17-1 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 872497-16-0
 CMF C38 H52 N6 O10 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 872497-18-2 HCAPLUS
CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.




RN 872497-19-3 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-18-2
 CMF C36 H50 N6 O9 S


Absolute stereochemistry.



Updated Search

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 872497-21-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-22-8 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-21-7
 CMF C35 H48 N6 O8 S2

Absolute stereochemistry.


Updated Search



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872497-33-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-34-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[[bis(1-methylethyl)amino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 872497-35-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-piperidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Updated Search



RN 872497-36-4 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-37-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[[3-(dimethylamino)-1-pyrrolidinyl]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-38-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Updated Search

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A




RN 872497-39-7 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-40-0 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2-cyanoethyl)cyclopropylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-41-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyloxy)-L-prolyl-1-amino-N-[(2-cyanoethyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-42-2 HCAPLUS

Updated Search

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-(aminosulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-43-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-44-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-N-[(2-cyanoethyl)cyclopropylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Updated Search

Absolute stereochemistry.



RN 872497-45-5 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-
 (4R)-4-(2-pyridinyloxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-
 ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 872497-46-6 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-
 (4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-2-ethenyl-N-(1-
 pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 872497-47-7 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 872497-48-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-49-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-50-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-51-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(ethylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search





RN 872497-52-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-[(cyclopropylmethyl)thio]-2-ethoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 872497-53-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-[(2-methylpropyl)sulfonyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-54-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-[(cyclopropylmethyl)sulfonyl]-2-ethoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-55-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-[(phenylmethyl)sulfonyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-56-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 872497-57-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-58-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-N-

Updated Search

[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-59-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-60-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-

Updated Search

(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-
[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-61-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-
(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-
ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-62-6 HCAPLUS

Updated Search

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-63-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN 872497-64-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-65-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-methoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Updated Search


RN 872497-66-0 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-67-1 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-7-methoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-68-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-69-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search



RN 872497-70-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-71-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 872497-72-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-73-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 872497-74-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-75-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-2-

Updated Search

ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-76-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-77-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyloxy]-L-prolyl-1-amino-N-[(2,5-

Updated Search

dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-78-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyloxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-79-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-N-

Updated Search

[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-80-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-81-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-

Updated Search

(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-82-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-
(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-
ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN 872497-83-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-84-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-85-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-86-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-

Updated Search

[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-87-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN 872497-88-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-89-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylpropoxyamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-90-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-91-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[[[(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-92-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-93-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-94-4 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 872497-95-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-

Updated Search

[[(cyanomethyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-96-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylpropylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-97-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(3-hydroxy-1-pyrrolidinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Updated Search

PAGE 1-A




PAGE 2-A



RN 872497-98-8 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[[ethyl(2-hydroxyethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-99-9 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-

Updated Search

[[methyl(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-00-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(3-carboxy-1-piperidinyl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-01-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-02-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[[4-chlorophenyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-03-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[[4-carboxyphenyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-04-9 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 872498-05-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(thieno[3,2-b]pyridin-7-yloxy)-L-prolyl-1-amino-N-

Updated Search

[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-06-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxythieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-07-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(3-phenyl-2-propynyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search



RN 872498-08-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-
(4R)-4-[(3-cyano-6-ethoxythieno[2,3-b]pyridin-4-yl)oxy]-L-prolyl-1-amino-N-
[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-09-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-
(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-
N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-10-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-11-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Updated Search



RN 872498-12-9 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[5-ethoxy-3-[(1-methylethyl)sulfonyl]thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-13-0 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-methyl-5-(1-methylethoxy)thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Updated Search



RN 872498-14-1 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-methyl-5-(2-propenyloxy)thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-15-2 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[5-ethoxy-3-(methylsulfonyl)thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Updated Search



RN 872498-16-3 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-2,3-dimethylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:1037097 HCAPLUS
 DOCUMENT NUMBER: 142:38535
 TITLE: Preparation of heterocyclic peptides as hepatitis C inhibitors
 INVENTOR(S): Llinas-Brunet, Montse; Bailey, Murray D.;

Updated Search

Bhardwaj, Punit; Bordeleau, Josee; Forgione, Pasquale;
 Ghiro, Elise; Gorys, Vida; Goudreau, Nathalie; Goulet,
 Sylvie; Halmos, Teddy; Rancourt, Jean
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;
 Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
 SOURCE: PCT Int. Appl., 186 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103996	A1	20041202	WO 2004-CA750	20040519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004240704	A1	20041202	AU 2004-240704	20040519
CA 2522577	A1	20041202	CA 2004-2522577	20040519
EP 1654261	A1	20060510	EP 2004-733750	20040519
EP 1654261	B1	20071114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010456	A	20060606	BR 2004-10456	20040519
CN 1791599	A	20060621	CN 2004-80013783	20040519
JP 2006528937	T	20061228	JP 2006-529495	20040519
AT 378334	T	20071115	AT 2004-733750	20040519
ES 2297424	T3	20080501	ES 2004-733750	20040519
US 20050020503	A1	20050127	US 2004-850101	20040520
MX 2005PA12545	A	20060208	MX 2005-PA12545	20051121
NO 2005006047	A	20060131	NO 2005-6047	20051219
IN 2005KN02624	A	20070727	IN 2005-KN2624	20051219
US 20070243166	A1	20071018	US 2007-766171	20070621
PRIORITY APPLN. INFO.:			US 2003-472709P	P 20030521
			WO 2004-CA750	W 20040519
			US 2004-850101	A1 20040520
OTHER SOURCE(S):	MARPAT 142:38535			
GI				



AB Peptides I [B, R3 are (un)substituted alkyl, cycloalkyl or alkylcycloalkyl; X is O or NH; R1 is Et or vinyl; RC is OH or NHSO2RS, where RS is (cyclo)alkyl, alkylcycloalkyl, Ph, naphthyl, pyridinyl or an amino group, which are optionally substituted; R2 is R20, -NR22COR20, -NR22CO2R20, -NR22R21 or -NR22CONR21R23, where N20 is any group given for B; R21 is H or R20; R22, R23 are H or Me; L0 is H, OH, alkoxy, NH2, mono- or dialkylamino; L1, L2 are independently H, alkyl, alkoxy, alkylthio, -sulfinyl, or -sulfonyl; one of L1 and L2 may also be H; L0 and L1 or L1 and L2 may be covalently bonded to form a 5- or 6-membered ring] or their racemates, diastereoisomers, optical isomers or pharmaceutically-acceptable salts or esters were prepared as inhibitors of the hepatitis C virus (HCV) NS3 protease and are useful for the treatment of hepatitis C viral infection. Thus, I (B-X = cyclopentyloxy, R1 = vinyl, R2 = NHCCH2CMe3, RC = OH, L1 = Me, L0 = MeO, L2 = H) was prepared via peptide coupling and Mitsunobu etherification reactions. The thiazole ring was formed by reaction of a 2-(bromoacetyl)quinoline derivative with N-neopentylthiourea. Compds. I show detectable plasma levels in the rat at 1 h and 2 h after an oral dose of 5 mg/kg.


IT 801286-05-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic peptides as hepatitis C inhibitors)

RN 801286-05-5 HCAPLUS

CN Cyclopropanecarboxamide, 3-methyl-N-[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]-L-valyl-(4R)-4-[[7-methoxy-8-methyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 20:02:56 ON 06 NOV 2008)

FILE 'REGISTRY' ENTERED AT 20:05:19 ON 06 NOV 2008

L1 STRUCTURE UPLOADED

L2 13 S L1

L3 309 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 20:17:10 ON 06 NOV 2008

L4 9 S L3

L5 3 S L4 AND BAILEY, M?/AU

=> s 14 not 15

L6 6 L4 NOT L5

=> s 16 and bhardwaj, p?/au

55 BHARDWAJ, P?/AU

L7 0 L6 AND BHARDWAJ, P?/AU

=> s 16 and forgione, p?/au

89 FORGIONE, P?/AU

L8 0 L6 AND FORGIONE, P?/AU

=> s 16 and ghio, e?/au

36 GHIRO, E?/AU

L9 0 L6 AND GHIRO, E?/AU

=> s 16 and goudreau, n?/au

44 GOUDREAU, N?/AU

L10 0 L6 AND GOUDREAU, N?/AU

Updated Search

```
=> s 16 and halmos, t?/au
      70 HALMOS, T?/AU
L11      0 L6 AND HALMOS, T?/AU

=> s 16 and linas-brunet, m?/au
      0 LINAS-BRUNET, M?/AU
L12      0 L6 AND LINAS-BRUNET, M?/AU

=> s 16 and poupart, m?/au
      65 POUPART, M?/AU
L13      0 L6 AND POUPART, M?/AU

=> s 16 and rancourt, j?/au
      133 RANCOURT, J?/AU
L14      0 L6 AND RANCOURT, J?/AU

=> d 16, ibib abs hitstr, 1-6
```

```
L6  ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:      2008:946323  HCAPLUS
DOCUMENT NUMBER:      149:224570
TITLE:      Preparation of hydroxyproline oxime ether-containing
              peptide analogs as hepatitis C virus (HCV) NS3-NS4A
              protease inhibitors for use in pharmaceutical
              compositions containing a cytochrome P450
              monooxygenase inhibitor
INVENTOR(S):      Sun, Ying; Or, Yat Sun; Wang, Zhe
PATENT ASSIGNEE(S):  USA
SOURCE:      U.S. Pat. Appl. Publ., 175pp., Cont.-in-part of U.S.
              Ser. No. 758,901.
              CODEN: USXXCO
DOCUMENT TYPE:      Patent
LANGUAGE:      English
FAMILY ACC. NUM. COUNT:  4
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20080187516	A1	20080807	US 2008-16631	20080118
US 20080125444	A1	20080529	US 2007-758901	20070606
PRIORITY APPLN. INFO.:			US 2006-811464P	P 20060606
			US 2006-921488P	P 20060811
			US 2007-758901	A2 20070606
OTHER SOURCE(S):		MARPAT 149:224570		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to a pharmaceutical composition containing a cytochrome P 450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof and a tripeptide protease inhibitor, particularly hepatitis C virus (HCV)

NS3-NS4A protease inhibitor, I [R1, R2 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl, cycloalkenyl, etc.; R1R2C = atoms to form (substituted) cycloalkyl, cycloalkenyl, heterocyclyl; m, p = 0-3; n = 1-3; G = ER3; E = null, O, CO, CO2, CONH, NH, NHCONH, NHSO2NH, NHSO2; R3 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl; A = R5, COR5, CONHR5, SO2R5, etc.; R5 = (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl; B = H, Me; L, Z = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl] or one of its pharmaceutically-acceptable salts, esters or prodrugs. The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, title compound (II) (solution phase preparation given) and other I inhibited HCV NS3 proteases with IC50 values in the range of <0.2 nM to about 50 nM. Ritonavir inhibited the metabolism of I in human liver microsomes.

IT 960385-40-4P 960385-41-5P 960385-45-9P

960385-46-0P 960385-47-1P 960385-48-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of hydroxyproline oxime ether-containing peptide
analogs as hepatitis C NS3-NS4A protease inhibitors)

RN 960385-40-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-41-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 960385-45-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-46-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.


Updated Search



RN 960385-47-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-48-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:941050 HCAPLUS

DOCUMENT NUMBER: 149:246795

TITLE: Preparation of 3-(quinolin-4-yl)-linked
proline-containing peptidomimetics as HCV protease
inhibitors

INVENTOR(S): Yang, Syaulan; Lee, Kuang-Yuan; Chen, Rong-Juinn; Lo,
Pin; Liao, Shao-Ying; Wu, Jen-Dar; King, Chi-Hsin
Richard

PATENT ASSIGNEE(S): Taigen Biotechnology Co., Ltd., Taiwan

SOURCE: PCT Int. Appl., 71pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008095058	A1	20080807	WO 2008-US52569	20080131
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080207528	A1	20080828	US 2008-23345	20080131
PRIORITY APPLN. INFO.:			US 2007-887741P	P 20070201
OTHER SOURCE(S):	MARPAT 149:246795			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to peptidomimetics I [A = cycloalk(en)ylene, alkylarylene; B = (hetero)aryl; X = O, OCH₂, CH₂O, OC(:O), COO, CONH₂, NHCO; Y, Z = independently NH and derivs., O, CH₂; D = (CH₂)_n; n = 1-2; R₁ = ORb₁, NRb₁Rb₂, NHCORb₁, NHCONHSO₂Rb₁, etc.; Rb₁, Rb₂ = independently H, heterocyclo/cyclo/alkyl, (hetero)aryl; R₂-12 = independently H, halo, alk(en/yn)yl, heterocycloalkenyl, etc.], which can be used to treat hepatitis C virus infection. Thus, II (Boc = tert-butoxycarbonyl) was prepared by a multiple-step synthesis in solution using 5,6,7,8-tetrahydroquinoline, 1-(2-amino-4-methoxyphenyl)ethanone, (4R)-N-(tert-butoxycarbonyl)-4-hydroxyproline, N-(tert-butoxycarbonyl)valine, Et (1R,2S)-1-amino-2-vinylcyclopropanecarboxylate and benzenesulfonamide. All eighty synthesized peptides exhibited inhibition of NS3/4A protease activity in the HCV replicon cell assay. (IC₅₀ values < 1 μM for 59 compds., in the range 1-10 μM for 14 compds. and > 10 μM for 7 compds.).

IT 1044755-82-9P 1044755-85-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of proline-containing peptidomimetics as HCV protease inhibitors)

RN 1044755-82-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-L-valyl-(4R)-4-[[2-(1,3-benzodioxol-5-yl)-7-methoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044755-85-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-L-valyl-(4R)-4-[[2-(1,3-benzodioxol-5-yl)-7-methoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-2-

Updated Search

ethenyl-N-[[(1-methylethyl)amino]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:221207 HCAPLUS

DOCUMENT NUMBER: 148:285476

TITLE: Preparation of arylalkoxy peptides as hepatitis C serine protease inhibitors

INVENTOR(S): Niu, Deqiang; Gai, Yonghua; Or, Yat Sun; Wang, Zhe

PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 85pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008022006	A2	20080221	WO 2007-US75653	20070810
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

Updated Search

PRIORITY APPLN. INFO.: US 2006-503413 A 20060811
 US 2007-836288 A 20070809
 OTHER SOURCE(S): MARPAT 148:285476
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to peptides I and II [A = H, COOR1, COR2, CONHR2, SO2R1, SO2NHR2; R1 = (un)substituted (hetero)aryl, heterocycloalkyl, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S or N, cycloalk(en)yl; R2, U, V = independently H, R1; G = OH, NHSO2R1; NHSO2N(R2)2; L = CH2, O, S, SO2, CO, COO, CONH, CHF, CF2, (un)substituted (hetero)arylene; X' = -X-(CH2)gC(Rx)(Ry)YZ; X = O, S, NR4; Y = absent, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S or N, (hetero)cycloalkyl; Z = (un)substituted (hetero)aryl; Rx, Ry = independently any of R2; or when Rx is not H and Y is not absent, RxCy = a ring; or when Rx is not H and Y is not absent, RxCYZ = a ring; g = 0-2; J = (CH2)j; j = 0-4; Q = (CH2)k; k = 1-3; D = (CH2)m; m = 0-2; T = (CH2)n; n = 1-2] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease (no data). The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, quinolinylmethoxy macrocycle III was prepared by O-alkylation of alc. IV (preparation given) with 8-bromomethylquinoline, saponification of the Et ester and activation of the acid with CDI/treatment with cyclopropanesulfonamide. Representative compds. of the invention were found to have HCV activity in the NS3/NS4A protease enzyme assay and in the cell based replicon assay (no data).

IT 1007855-10-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of arylalkoxy peptides as hepatitis C serine protease inhibitors)

RN 1007855-10-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(2-naphthalenylmethoxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:156665 HCAPLUS

DOCUMENT NUMBER: 148:239500

TITLE: Preparation of quinoxalinyll tripeptides as hepatitis C serine protease inhibitors

INVENTOR(S): Gai, Yonghua; Niu, Deqiang; Or, Yat Sun; Wang, Zhe

PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 85pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080032936	A1	20080207	US 2006-499917	20060804
PRIORITY APPLN. INFO.:			US 2006-499917	20060804
OTHER SOURCE(S):	MARPAT	148:239500		

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to tripeptides I [A = COOR1, COR2, CONHR2, SO2R1, SO2NHR2; R1, R2 = independently (un)substituted (hetero)aryl, heterocycloalkyl, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S, N; cycloalk(en)yl; R, R' = independently R1, H, D, alkylcycloalk(en)yl; G = OH, NHSO2R3, NH2 and derivs.; R3 = R1; XCCY = (un)substituted (hetero)aryl; W = absent, O, S NH, Me, CONH, CONMe; Z = H, (un)substituted aryl, alkyl, heterocycloalkyl, etc.; WZ = CN, N3, halo, NHN:CHR2; B = (CH2)m; m = 0-2; D = (CH2)n; n = 1-2] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease (no data). The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, a

multi-step synthesis using N-(tert-butoxycarbonyl)-L-tert-leucine, cis-L-hydroxyproline Me ester, 3-(thiophen-2-yl)-1H-quinoxalin-2-one and (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid Et ester hydrochloride was given for II. Representative compds. of the invention showed particularly advantageous biol. activity in enzyme inhibition and cell-based replicon assays for HCV activity (no data).

IT 1006051-37-1P 1006051-38-2P 1006051-86-0P
 1006051-87-1P 1006051-90-6P 1006051-91-7P
 1006051-92-8P 1006051-96-2P 1006051-97-3P
 1006052-00-1P 1006052-01-2P 1006052-02-3P
 1006052-14-7P 1006052-20-5P 1006052-21-6P
 1006052-32-9P 1006052-35-2P 1006052-37-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinoxaliny tripeptides as hepatitis C serine protease inhibitors)

RN 1006051-37-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-38-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-86-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-(aminosulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-87-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-90-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-91-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1006051-92-8 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2H-tetrazol-5-ylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-96-2 HCAPLUS
 CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-(aminosulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.


Updated Search



RN 1006051-97-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-00-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-01-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-02-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2H-tetrazol-5-ylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-14-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[6,7-dimethoxy-3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1006052-20-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(2-thienyl)ethyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.


Updated Search



RN 1006052-21-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 1006052-32-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


Updated Search



RN 1006052-35-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[[(2-fluoroethyl)amino]carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(2-thienyl)ethyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1006052-37-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[[[(2-fluoroethyl)amino]carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

Updated Search



L6 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1454513 HCAPLUS
 DOCUMENT NUMBER: 148:79321
 TITLE: Preparation of hydroxyproline oxime ether-containing peptide analogs as hepatitis C virus (HCV) NS3-NS4A protease inhibitors
 INVENTOR(S): Or, Yat Sun; Sun, Ying; Wang, Zhe
 PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 190pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007146695	A1	20071221	WO 2007-US70481	20070606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-811464P P 20060606
 US 2006-503385 A 20060811
 OTHER SOURCE(S): MARPAT 148:79321
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. [I; R1, R2 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl, cycloalkenyl, etc.; R1R2C = atoms to form (substituted) cycloalkyl, cycloalkenyl, heterocyclyl; m, p = 0-3; n = 1-3; G = ER3; E = null, O, CO, CO2, CONH, NH, NHCONH, NHSO2NH, NHSO2; R3 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl; A = R5, COR5, CONHR5, SO2R5, etc.; R5 = (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl; B = H, Me; L, Z = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl], were prepared Thus, title compound (II) (solution phase preparation given) and other I inhibited HCV NS3 proteases with IC50 values in the range of <0.2 nM to about 50 nM.

IT 960385-40-4P 960385-41-5P 960385-45-9P
960385-46-0P 960385-47-1P 960385-48-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of hydroxyproline oxime ether-containing peptide
analogs as hepatitis C NS3-NS4A protease inhibitors)

RN 960385-40-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-41-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-

Updated Search

[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-45-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-46-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 960385-47-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-48-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:451218 HCAPLUS

DOCUMENT NUMBER: 142:482325

TITLE: Preparation of prolyl peptides as hepatitis C virus inhibitors

INVENTOR(S): Scola, Paul Michael; McPhee, Fiona; Meanwell, Nicholas A.; Hewawasam, Piyasena; Campbell, Jeffrey Allen

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046712	A1	20050526	WO 2004-US38165	20041112
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050187165	A1	20050825	US 2004-985106	20041110
US 7132504	B2	20061107		
EP 1687018	A1	20060809	EP 2004-811049	20041112
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			

JP 2007534636	T	20071129	JP 2006-539980	20041112
NO 2006002267	A	20060804	NO 2006-2267	20060519
PRIORITY APPLN. INFO.:			US 2003-519124P	P 20031112
			WO 2004-US38165	W 20041112

OTHER SOURCE(S): CASREACT 142:482325; MARPAT 142:482325
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention discloses peptides I [R1, R2 are independently alkyl, cycloalkyl, alkylcycloalkyl, alkoxy, aryl, alkylaryl, cycloalkylaryl, alkoxyaryl, cycloalkoxyaryl, heteroaryl or alkylheteroaryl; or NR1R2 is monocyclic heterocyclyl; m, n are 1 or 2; R3 is H, (halo)alk(en)yl or (halo)cycloalkyl; R4 is (un)substituted alkyl, alkenyl or cycloalkyl; Y is H, nitrophenyl, nitropyridyl or (un)substituted alkyl; B is H, alkyl, acyl, (thio)carbamoyl, sulfonyl or sulfamoyl; X is O, S, SO, SO2, OCH2, CH2O or NH; R' is (un)substituted heterocyclyl or aryl (with provisos)] or their pharmaceutically-acceptable salts, solvates or prodrugs and methods for using them to inhibit the hepatitis C virus (HCV). Thus, compound II was prepared via peptide coupling in solution and showed IC50 and EC50 < 0.15 μ M for inhibition of HCV NS3/4A protease.

IT 851795-10-3P 851795-11-4P 851795-12-5P
851795-13-6P 851795-14-7P 851795-15-8P
851795-16-9P 851795-17-0P 851795-18-1P
851795-19-2P 851795-20-5P 851795-21-6P
851795-22-7P 851795-23-8P 851795-24-9P
851795-25-0P 851795-26-1P 851795-27-2P
851795-28-3P 851795-29-4P 851795-30-7P
851795-31-8P 851795-33-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of prolyl peptides as hepatitis C virus inhibitors)


RN 851795-10-3 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-


CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-



RN 851795-13-6 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-(1-azetidynylsulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-14-7 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-15-8 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-16-9 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[[methyl(1-methylethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-17-0 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-18-1 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[[methyl(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-19-2 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-piperidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-20-5 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(tetrahydro-2H-1,2-oxazin-2-yl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-21-6 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinesulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-22-7 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-23-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-24-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-25-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-26-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-27-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyloxy)-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-28-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyloxy)-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-29-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyloxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-30-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyloxy)-L-prolyl-1-amino-2-ethenyl-N-[[methyl(1-methylethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-31-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(1-isoquinolinylloxy)-L-prolyl-1-amino-2-ethenyl-N-[[methyl(1-methylethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-33-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(4-pyridinyl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
62.50	250.44

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-7.20	-7.20

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 20:19:54 ON 06 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAOLD will be discontinued and removed from associated database clusters.

Updated Search

- . November 22, 2008 - removed from database clusters
- . December 31, 2008 - removed from STN

Content previously available only in CAOLD is now available in CA/Caplus. To learn more about the options available for transferring saved search queries and answer sets to CA/Caplus, contact your STN Service Center.

=> d his

(FILE 'HOME' ENTERED AT 20:02:56 ON 06 NOV 2008)

FILE 'REGISTRY' ENTERED AT 20:05:19 ON 06 NOV 2008

L1 STRUCTURE UPLOADED

L2 13 S L1

L3 309 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 20:17:10 ON 06 NOV 2008

L4 9 S L3

L5 3 S L4 AND BAILEY, M?/AU

L6 6 S L4 NOT L5

L7 0 S L6 AND BHARDWAJ, P?/AU

L8 0 S L6 AND FORGIONE, P?/AU

L9 0 S L6 AND GHIRO, E?/AU

L10 0 S L6 AND GOUDREAU, N?/AU

L11 0 S L6 AND HALMOS, T?/AU

L12 0 S L6 AND LINAS-BRUNET, M?/AU

L13 0 S L6 AND POUPART, M?/AU

L14 0 S L6 AND RANCOURT, J?/AU

FILE 'CAOLD' ENTERED AT 20:19:54 ON 06 NOV 2008

=> s 13

L15 0 L3

=>